CLINICAL RESEARCH, DATA SECURITY
AND SAFETY GUIDELINES
Audits and Inspections in Clinical Research – ANSWERS ✓
During an inspection by the Food and Drug Administration,
what will inspectors primarily review? – ANSWER ✓
Research regulatory records and study documentation.
According to the International Council for Harmonisation
E6 guideline, how is an audit defined? – ANSWER ✓
A structured, independent review of study-related processes and
documents.
What is the primary role of the Office for Human Research
Protections? – ANSWER ✓
Ensuring the safety and rights of human research participants.
What is the main goal of monitoring, audits, and inspections
in clinical trials? – ANSWER ✓
To protect research participants and maintain the integrity of
study data.
How does the International Council for Harmonisation E6
define an inspection? – ANSWER ✓
A formal evaluation of facilities, documentation, records, and
resources associated with the study.
Adverse Events & Safety Reporting – Revised Q&A
,In a blinded clinical trial evaluating two licensed medications
administered at doses higher than normally prescribed, the
following incidents occurred: On Day 4, subject 812 developed
acute respiratory distress but stabilized after urgent medical
care; On Day 7, subject 29 experienced a severe migraine
requiring hospital admission and antihypertensive treatment.
Neither incident is consistent with known drug actions or prior
medical conditions. For which subjects should a serious adverse
event notification be filed?
Answer: Both subjects.
While administering a new investigational treatment, the
following cases were observed: On Day 9, subject 812
experienced an unanticipated cerebrovascular accident requiring
hospitalization; On Day 17, subject 502 reported nausea and
headache that resolved with routine care; On Day 25, subject 29
felt mild lightheadedness upon standing. Which of these
situations satisfies the criteria of being both “serious” and
“unexpected,” requiring the trial funding organization to submit
an Investigational New Drug safety report to the Food and Drug
Administration?
Answer: Subject 812 only.
A participant (subject 401) is found to have persistently
increased white blood cell levels over two study visits, without
showing any symptoms. This laboratory abnormality is not
documented in the Investigator’s Brochure as a known side
effect. What is the most appropriate action for the principal
,investigator?
Answer: Notify the trial funding organization of the elevated
white blood cell count as an unexpected adverse event.
Monitoring Clinical Studies by Trial Funding Organizations
– ANSWERS ✓
Which monitoring visit does not include a check of
investigational therapy inventory? – ANSWER ✓
The prestudy site visit.
When should the trial monitor conduct the most thorough
review of the study protocol with the research site staff? –
ANSWER ✓
During the site initiation visit.
What is required during a prestudy site visit? – ANSWER ✓
Assessment of the site’s capability to conduct the study.
When should all unused investigational therapies be
returned to the trial funding organization? – ANSWER ✓
At the termination site visit.
During which visits are the majority of case report form
entries verified against original source documents? –
ANSWER ✓
During periodic monitoring visits.
, Ethical Principles in Clinical Research – ANSWERS ✓
What are the three ethical principles outlined in the Belmont
Report? – ANSWER ✓
Respect for individuals, beneficence (promoting well-being),
and justice (fair treatment).
Which is an example of applying the principle of beneficence
in a study involving human participants? – ANSWER ✓
Ensuring the study design maximizes benefits while minimizing
risks.
How is the principle of respect for individuals described in
the Belmont Report? – ANSWER ✓
Providing complete information, ensuring understanding, and
allowing voluntary participation.
Principal Investigator Responsibilities in Food and Drug
Administration-Regulated Studies – ANSWERS ✓
When must a principal investigator update the Institutional
Review Board about the study progress? – ANSWER ✓
Throughout the study and upon completion.
Form Food and Drug Administration 1572, Statement of
Investigator, establishes a legal agreement between the
investigator and which authority? – ANSWER ✓
The Food and Drug Administration.
AND SAFETY GUIDELINES
Audits and Inspections in Clinical Research – ANSWERS ✓
During an inspection by the Food and Drug Administration,
what will inspectors primarily review? – ANSWER ✓
Research regulatory records and study documentation.
According to the International Council for Harmonisation
E6 guideline, how is an audit defined? – ANSWER ✓
A structured, independent review of study-related processes and
documents.
What is the primary role of the Office for Human Research
Protections? – ANSWER ✓
Ensuring the safety and rights of human research participants.
What is the main goal of monitoring, audits, and inspections
in clinical trials? – ANSWER ✓
To protect research participants and maintain the integrity of
study data.
How does the International Council for Harmonisation E6
define an inspection? – ANSWER ✓
A formal evaluation of facilities, documentation, records, and
resources associated with the study.
Adverse Events & Safety Reporting – Revised Q&A
,In a blinded clinical trial evaluating two licensed medications
administered at doses higher than normally prescribed, the
following incidents occurred: On Day 4, subject 812 developed
acute respiratory distress but stabilized after urgent medical
care; On Day 7, subject 29 experienced a severe migraine
requiring hospital admission and antihypertensive treatment.
Neither incident is consistent with known drug actions or prior
medical conditions. For which subjects should a serious adverse
event notification be filed?
Answer: Both subjects.
While administering a new investigational treatment, the
following cases were observed: On Day 9, subject 812
experienced an unanticipated cerebrovascular accident requiring
hospitalization; On Day 17, subject 502 reported nausea and
headache that resolved with routine care; On Day 25, subject 29
felt mild lightheadedness upon standing. Which of these
situations satisfies the criteria of being both “serious” and
“unexpected,” requiring the trial funding organization to submit
an Investigational New Drug safety report to the Food and Drug
Administration?
Answer: Subject 812 only.
A participant (subject 401) is found to have persistently
increased white blood cell levels over two study visits, without
showing any symptoms. This laboratory abnormality is not
documented in the Investigator’s Brochure as a known side
effect. What is the most appropriate action for the principal
,investigator?
Answer: Notify the trial funding organization of the elevated
white blood cell count as an unexpected adverse event.
Monitoring Clinical Studies by Trial Funding Organizations
– ANSWERS ✓
Which monitoring visit does not include a check of
investigational therapy inventory? – ANSWER ✓
The prestudy site visit.
When should the trial monitor conduct the most thorough
review of the study protocol with the research site staff? –
ANSWER ✓
During the site initiation visit.
What is required during a prestudy site visit? – ANSWER ✓
Assessment of the site’s capability to conduct the study.
When should all unused investigational therapies be
returned to the trial funding organization? – ANSWER ✓
At the termination site visit.
During which visits are the majority of case report form
entries verified against original source documents? –
ANSWER ✓
During periodic monitoring visits.
, Ethical Principles in Clinical Research – ANSWERS ✓
What are the three ethical principles outlined in the Belmont
Report? – ANSWER ✓
Respect for individuals, beneficence (promoting well-being),
and justice (fair treatment).
Which is an example of applying the principle of beneficence
in a study involving human participants? – ANSWER ✓
Ensuring the study design maximizes benefits while minimizing
risks.
How is the principle of respect for individuals described in
the Belmont Report? – ANSWER ✓
Providing complete information, ensuring understanding, and
allowing voluntary participation.
Principal Investigator Responsibilities in Food and Drug
Administration-Regulated Studies – ANSWERS ✓
When must a principal investigator update the Institutional
Review Board about the study progress? – ANSWER ✓
Throughout the study and upon completion.
Form Food and Drug Administration 1572, Statement of
Investigator, establishes a legal agreement between the
investigator and which authority? – ANSWER ✓
The Food and Drug Administration.
